Intesa Sanpaolo completes share buyback program with over 23 million shares purchased

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo announced the completion of its share buyback program, which aimed to purchase shares for cancellation. The program, initially disclosed on May 26, 2025, and launched on June 2, 2025, was executed by Morgan Stanley Europe SE, acting independently from Intesa Sanpaolo.

Between October 13 and October 17, 2025, the bank bought a total of 23,957,724 shares. This amount represents about 0.13% of the company’s share capital. The average purchase price was 5.4265 euros per share, with the total transaction value reaching 130,005,907.74 euros.

The transactions took place on the Euronext Milan market operated by Borsa Italiana.

According to the company’s statement: “With reference to the execution of the programme of purchase of own shares for annulment (buyback), which was disclosed to the market on 26 May 2025 and launched on 2 June 2025, Intesa Sanpaolo, pursuant to applicable regulations, communicates that – on the basis of information provided by Morgan Stanley Europe SE, the third-party intermediary appointed to execute the programme in full independence and without any involvement of the Intesa Sanpaolo Group – from 13 October to 17 October 2025 the Bank executed the purchase transactions summarised in the table below on the regulated market Euronext Milan managed by Borsa Italiana.”

The buyback program has now concluded.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.